SLC38A2 and cancer: Mengsen et al. conducted a comprehensive 5-year pan-cancer cohort analysis, revealing that the overexpression of SLC38A2 is emblematic of cancer’s metabolic characteristics and correlates with diminished survival rates (Huang et al., 2020).